In an environment full of possible acquisitions and partnership deals, biotech companies are making sure to communicate their potential value.
From rumors of pharmaceutical acquisitions to questions over cash, biotechnology companies are facing increasing pressure to communicate their economic position, as well as the depth of their drugs and therapy pipeline.
Now, say industry insiders, is the time for biotechs with late-stage therapies and acquisition, merger, or partnership potential to discuss the strength of the company story and the progress that ...